Glonghui November 15 丨 Zhongheng Group (600252.SH) announced that recently, the company's holding subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. (“Laimei Pharmaceutical”) and its holding subsidiary Chengdu Jinxing Health Pharmaceutical Co., Ltd. (“Chengdu Jinxing”, “Target Company”), Chengdu Jinxing Minority Shareholder Sanum-Kehlbeck GmbH & Co.kg (“Shanum Germany”) and Chengdu Yaoyun Pharmaceutical Technology Co., Ltd. (“Yaoyun Pharmaceutical”) recently announced that the “Chengdu Jinxing Health Pharmaceutical Co., Ltd. Capital Increase and Subscription Agreement” (“originally intended to sign an agreement”) ”) The relevant provisions have been refined and improved, and the revised agreement has been signed. Yaoyun Pharmaceutical will increase the capital of Chengdu Jinxing to RMB 112,810,271.79.

After the capital increase of Chengdu Jinxing is completed, Yaoyun Pharmaceutical will hold 61% of the target company's shares, Laimei Pharmaceutical will hold 35.1% of the target company's shares, Germany's Shanum Company will hold 3.9% of the target company's shares, and Chengdu Jinxing will no longer be included in the scope of the company's consolidated statements.